In the News

410 News Items found
Jedd Wolchok and Charlotte Ariyan in the lab
In the Clinic
A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.
MSK scientists Andrew Kung and Elli Papaemmanuil
By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.
Samuel Danishefsky
As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
An MSK scientist pipettes in the lab
MSK Research Highlights, May 18, 2023
New MSK research shows how high-risk neuroblastoma evolves to be so deadly; finds continued safety and efficacy for sotorasib in patients with KRAS G12C-mutated advanced non-small cell lung cancer; and demonstrates promise in eradicating tumors by delivering a viral-based immunotherapeutic to melanoma and breast cancer in mouse models.
Pictured: Jedd Wolchok and James Allison
In the News
In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan Kettering Institute's Immunology Program, and medical oncologist and immunologist Jedd Wolchok.
Jeffrey Drebin
In a recent interview, MSK's Dr. Jeffrey Drebin addressed why it’s important for people to keep up with their routine screenings and not put off cancer treatment or surgery.
Dr. Bobby Daly seen smiling with patient.
Learn how MSK is making clinical trials more accessible through innovative new approaches that bring care to people's homes and make participating possible even for people who live far from MSK.
Albert Kuchler with MSK medical oncologist Bob Li.
Computational biology is helping to bring predictive power and precision to oncology.
Scott Lowe
MSK researchers and collaborators have developed a new type of CAR T cell designed to attack a cell surface protein called uPAR — allowing them to target both tumors and cancer-supporting cells in the tumor microenvironment.
NBC’s Today Show Spotlights MSK and Addresses Access to Care at Comprehensive Cancer Centers
On July 22, 2021, Memorial Sloan Kettering Cancer Center was prominently featured on NBC News/The Today Show about “How to Navigate Nation’s Top Hospitals.”